Verrica Pharmaceuticals Inc. VRCA
Set alert
At close · Oct 30
After hours · Oct 30, 5:32 PM ET
- YTD
- -59.69%
- 1 year
- -5.10%
- Open
- 3.42
- Prev close
- 3.42
- Mkt cap
- 57.55M
- Vol
- 33.79K
- Avg vol
- 69.92K
- EPS
- -1.75
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.25
- High
- 3.47
- Forward P/E
- -1.19
- Beta
- 1.46
- Short ratio
- 3.19
- Inst. own
- 15.80%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 14, 2024
- 50-d avg
- 1.12
- 200-d avg
- 4.58
- 1y target
- 6.33
News
1 week ago globenewswire.com
Verrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit Facility
– Company's achievement of pre-defined revenue, growth and operational milestones increases facility commitment by $15.0 million – – Capital now available to support continued growth of the YCANTH®…
2 weeks ago benzinga.com
Verrica Pharmaceuticals Q2 2026 Earnings Call Transcript
Verrica Pharmaceuticals (NASDAQ:VRCA) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For…
3 weeks ago defenseworld.net
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Stock Has Average Price Target of $12.67 According to Brokerages
Verrica Pharmaceuticals Inc. (NASDAQ: VRCA - Get Free Report) has been given an average recommendation of "Hold" by the five ratings firms that are currently covering the firm, Marketbeat.com…
1 month ago globenewswire.com
Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences
– Analysis shows YCANTH achieved complete clearance of molluscum contagiosum approximately 4 times faster than vehicle, regardless of disease duration –
1 month ago globenewswire.com
Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences
– Post-hoc analysis shows YCANTH® drove high rates of complete clearance in molluscum contagiosum patients regardless of disease duration –
1 month ago globenewswire.com
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
WEST CHESTER, Pa., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of…
2 months ago globenewswire.com
Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027
– Per-protocol interim statistical power analysis confirms no additional patients are recommended for full enrollment – – Second pivotal Phase 3 trial (COVE-3) has already exceeded 50% of current…
2 months ago marketbeat.com
Verrica Pharmaceuticals Q2 Earnings Call Highlights
Verrica Pharmaceuticals NASDAQ: VRCA reported second-quarter revenue growth in its YCANTH treatment for molluscum contagiosum, while outlining progress in pivotal studies of the product for common…
2 months ago seekingalpha.com
Verrica Pharmaceuticals Inc. (VRCA) Q2 2026 Earnings Call Transcript
Verrica Pharmaceuticals Inc. (VRCA) Q2 2026 Earnings Call Transcript
-
2 months ago benzinga.com
Verrica Pharmaceuticals Q2 Adj. EPS $(0.48) Misses $(0.38) Estimate, Sales $5.862M Beat $5.733M Estimate
Verrica Pharmaceuticals (NASDAQ:VRCA) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.38) by 26.32 percent. This is a 292 percent decrease over…
3 months ago globenewswire.com
Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
WEST CHESTER, Pa., July 30, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for…
3 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Autonomix Medical (NASDAQ:AMIX) stock rose 49.1% to $4.1 during Tuesday's after-market session. The market value of their outstanding shares is at $1.5 million. CalciMedica (NASDAQ:CALC)…
-
3 months ago benzinga.com
Verrica Pharmaceuticals Grants Medomie Pharma Rights To Seek Israeli Regulatory Approval For And To Distribute YCANTH For The Treatment Of Molluscum Contagiosum With Up To $8.2M In Milestones
Under the terms of the Agreement, Verrica has granted Medomie an exclusive right to obtain and maintain marketing authorizations for YCANTH in Israel. Verrica will manufacture YCANTH and provide…
3 months ago globenewswire.com
Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel
WEST CHESTER, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of…
3 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 55.8% to $1.11 during Wednesday's pre-market session. The company's market cap stands at $2.5 million. Innovative Eyewear (NASDAQ:LUCY)…
4 months ago globenewswire.com
Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
- Development Partner Torii Pharmaceutical also recently announced dosing of the first Japanese patient in this trial evaluating YCANTH (TO-208) in Japan - - Verrica maintains ownership of global…
5 months ago globenewswire.com
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
WEST CHESTER, Pa., May 28, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of…
-
5 months ago benzinga.com
HC Wainwright & Co. Assumes Verrica Pharmaceuticals at Buy, Announces Price Target of $12
HC Wainwright & Co. analyst Raghuram Selvaraju assumes Verrica Pharmaceuticals (NASDAQ:VRCA) with a Buy rating and announces Price Target of $12.
5 months ago globenewswire.com
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
WEST CHESTER, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of…
-
5 months ago benzinga.com
Transcript: Verrica Pharmaceuticals Q1 2026 Earnings Conference Call
Transcript: Verrica Pharmaceuticals Q1 2026 Earnings Conference Call
5 months ago marketbeat.com
Verrica Pharmaceuticals Q1 Earnings Call Highlights
Verrica Pharmaceuticals NASDAQ: VRCA reported higher first-quarter revenue and record demand for its molluscum contagiosum treatment YCANTH, while outlining progress on late-stage development…
5 months ago seekingalpha.com
Verrica Pharmaceuticals Inc. (VRCA) Q1 2026 Earnings Call Transcript
Verrica Pharmaceuticals Inc. (VRCA) Q1 2026 Earnings Call Transcript
5 months ago zacks.com
Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates
Verrica Pharmaceuticals Inc. (VRCA) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to a loss of $1 per share a year ago.
-
5 months ago benzinga.com
Verrica Pharmaceuticals Q1 Adj. EPS $(0.41) Misses $(0.38) Estimate, Sales $5.023M Beat $4.520M Estimate
Verrica Pharmaceuticals (NASDAQ:VRCA) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.38) by 7.89 percent. This is a 53.41 percent increase over…
5 months ago globenewswire.com
Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results
– Company reports record demand for YCANTH® as dispensed applicator units grew to 15,302 in Q1 2026, up 12.1% over the previous quarter and 51.3% year-over-year, and has now exceeded 100,000…
-
6 months ago benzinga.com
Verrica Pharma To Present Phase 2 Clinical Data Highlighting Potential Abscopal Effects Of Oncolytic Peptide, VP-315, In Treatment Of Basal Cell Carcinoma At 2026 SID Annual Meeting
Phase 2 Data Highlight the Observed Abscopal-like Effect of VP-315 in Non-treated Basal Cell Carcinoma Tumors WEST CHESTER, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc.…
6 months ago globenewswire.com
Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting
Phase 2 Data Highlight the Observed Abscopal-like Effect of VP-315 in Non-treated Basal Cell Carcinoma Tumors WEST CHESTER, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc.…
6 months ago globenewswire.com
Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026
WEST CHESTER, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the…
7 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
7 months ago benzinga.com
Earnings Scheduled For March 11, 2026
Earnings Scheduled For March 11, 2026
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
11 months ago benzinga.com
Why Heartbeam Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket
Why Heartbeam Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
1 year ago benzinga.com
Earnings Scheduled For August 12, 2025
Earnings Scheduled For August 12, 2025
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
1 year ago benzinga.com
This Super Micro Computer Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday (CORRECTED)
This Super Micro Computer Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday (CORRECTED)
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
1 year ago benzinga.com
Why Palantir Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Why Palantir Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
-
2 years ago benzinga.com
Earnings Scheduled For February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.
-
2 years ago benzinga.com
Insiders Buying Pfizer And 3 Other Stocks
Although U.S. stocks closed higher on Tuesday, there were a few notable insider trades.
-
2 years ago benzinga.com
Why Quanex Building Products Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Quanex Building Products Corporation (NYSE: NX) moved lower during Friday’s session after the company reported fourth-quarter financial results. Quanex Building Products shares fell 10.7%…
-
2 years ago benzinga.com
Earnings Scheduled For November 9, 2023
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million.